Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 16Lymphoid 10Myeloid 9Plasma cell 7Sarcoma 5Genitourinary 3Gastrointestinal 3Dermatologic 2Classical hematology 2CNS 2Other solid neoplasm 1Other neoplasm 1NET 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

PRETEXT I Hepatoblastoma 1Gastroenteropancreatic Neuroendocrine Tumors 1Adenomatous Polyposis Coli 1

Interventions

Oxaliplatin 135Fluorouracil 129Gemcitabine 114Bevacizumab 111Specimen Handling 101Leucovorin 101Capecitabine 87Magnetic Resonance Spectroscopy 81pembrolizumab 78Cisplatin 74Nivolumab 70Irinotecan 68Cetuximab 58130-nm albumin-bound paclitaxel 58durvalumab 57Paclitaxel 57Biopsy 55atezolizumab 42Radiotherapy 40Albumin-Bound Paclitaxel 36Taxes 35Folfox protocol 34Carboplatin 34Drug Therapy 28lenvatinib 27sintilimab 26dehydroftorafur 26Radiation 26Cyclophosphamide 26tislelizumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Sirolimus × Gastrointestinal × 90 days × Clear all
NCT06308445 2026-05-08

RAPA-4-PAF

University Hospital, Toulouse

Phase 2 Not yet recruiting
25 enrolled
Gastrointestinal

Adenomatous Polyposis Coli

NCT00980460 2026-05-04

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
236 enrolled 18 charts
Gastrointestinal

PRETEXT I Hepatoblastoma

NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡